Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Neuro-Oncology Année : 2022

Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

Marijke Coomans
  • Fonction : Auteur
Linda Dirven
Neil Aaronson
  • Fonction : Auteur
Brigitta Baumert
  • Fonction : Auteur
Martin van den Bent
Andrew Bottomley
  • Fonction : Auteur
Alba Brandes
  • Fonction : Auteur
Corneel Coens
  • Fonction : Auteur
Thierry Gorlia
  • Fonction : Auteur
Ulrich Herrlinger
  • Fonction : Auteur
Florence Keime-Guibert
  • Fonction : Auteur
Annika Malmström
  • Fonction : Auteur
Francesca Martinelli
  • Fonction : Auteur
Roger Stupp
  • Fonction : Auteur
Andrea Talacchi
  • Fonction : Auteur
Michael Weller
Wolfgang Wick
Jaap Reijneveld
  • Fonction : Auteur
Martin Taphoorn
  • Fonction : Auteur

Résumé

Background: Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression-free time, and factors associated with HRQoL deterioration in this period. Methods We included longitudinal HRQoL data from previously published clinical trials in glioma. The percentage of patients with stable HRQoL until progression was determined per scale and at the individual patient level (i.e. considering all scales simultaneously). We assessed time to a clinically relevant deterioration in HRQoL, expressed in deterioration-free survival and time-to-deterioration (the first including progression as an event). We also determined the association between sociodemographic and clinical factors and HRQoL deterioration in the progression-free period. Results: Five thousand five hundred and thirty-nine patients with at least baseline HRQoL scores had a median time from randomization to progression of 7.6 months. Between 9–29% of the patients deteriorated before disease progression on the evaluated HRQoL scales. When considering all scales simultaneously, 47% of patients deteriorated on ≥1 scale. Median deterioration-free survival period ranged between 3.8–5.4 months, and median time-to-deterioration between 8.2–11.9 months. For most scales, only poor performance status was independently associated with clinically relevant HRQoL deterioration in the progression-free period. Conclusions: HRQoL was maintained in only 53% of patients in their progression-free period, and treatment was not independently associated with this deterioration in HRQoL. Routine monitoring of the patients’ functioning and well-being during the entire disease course is therefore important, so that interventions can be initiated when problems are signaled.
Fichier principal
Vignette du fichier
noac097.pdf (5.05 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03976659 , version 1 (03-07-2024)

Identifiants

Citer

Marijke Coomans, Linda Dirven, Neil Aaronson, Brigitta Baumert, Martin van den Bent, et al.. Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. Neuro-Oncology, 2022, 24 (12), pp.2159-2169. ⟨10.1093/neuonc/noac097⟩. ⟨hal-03976659⟩
10 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More